Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Key Highlights
- ➤Leila Alland, MD, appointed interim Chief Medical Officer
- ➤Cardiff Oncology’s randomized Phase 2 trial remains ongoing
- ➤Median PFS not reached in proposed Phase 3 regimen arm
- ➤All remaining trial patients have received treatment for over 18 months
- ➤Registrational Phase 3 study planned for first quarter of 2027
Expert Statements
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“We are pleased to welcome Leila as interim Chief Medical Officer”
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“She brings a strong track record of leadership in advancing novel cancer therapies and is well-positioned to guide our clinical strategy as we enter a pivotal phase in clinical development.”
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“Our randomized Phase 2 trial in first line RAS-mutated metastatic colorectal cancer is still ongoing, and median PFS has not been reached in the onvansertib 30 mg plus FOLFIRI and bevacizumab arm, our proposed Phase 3 regimen.”
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“All patients remaining on trial have now been on treatment for more than 18 months.”
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“We are at a defining period for Cardiff as we prepare to initiate our registrational Phase 3 study in the first quarter of 2027.”
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“Leila’s expertise will be instrumental as we advance this program and also evaluate the broader potential of PLK1 inhibition in other cancers with few treatment options.”
Leila Alland, Interim Chief Medical Officer of Cardiff Oncology
“Despite advances in the treatment of metastatic colorectal cancer, significant unmet needs remain, particularly for patients with RAS-mutated disease”
Leila Alland, Interim Chief Medical Officer of Cardiff Oncology
“I believe onvansertib's differentiated approach, which targets a key vulnerability of RAS-mutated tumors through PLK1 inhibition, holds significant promise for addressing these challenges and improving patient outcomes.”
Leila Alland, Interim Chief Medical Officer of Cardiff Oncology
“I am excited to take on this role at such an important stage in its development and help translate that promise into meaningful clinical benefit for patients.”
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs. Dr. Alland succeeds Roger Sidhu, MD, who has stepped down from his role as Chief Medical Officer.
“We are pleased to welcome Leila as interim Chief Medical Officer,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “She brings a strong track record of leadership in advancing novel cancer therapies and is well-positioned to guide our clinical strategy as we enter a pivotal phase in clinical development. Our randomized Phase 2 trial in first line RAS-mutated metastatic colorectal cancer is still ongoing, and median PFS has not been reached in the onvansertib 30 mg plus FOLFIRI and bevacizumab arm, our proposed Phase 3 regimen. All patients remaining on trial have now been on treatment for more than 18 months. We are at a defining period for Cardiff as we prepare to initiate our registrational Phase 3 study in the first quarter of 2027. Leila’s expertise will be instrumental as we advance this program and also evaluate the broader potential of PLK1 inhibition in other cancers with few treatment options.”
Get started
Create a free account to read the full story.